REFERENCES
- Mannino D M. Chronic obstructive pulmonary disease: definition and epidemiology. Respir Care 2003; 48: 1185–1191
- American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. AmJ of Respir Crit Care Med 1995; 152: S77–S121
- Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. AmJ of Respir Crit Care Med 2001; 163: 1256–1276
- O'Donohue W J, the National Association for Medical Direction of Respiratory Care (NAMDRC) Consensus Group. Guidelines for the use of nebulizers in the home and at domiciliary sites. Chest 1996; 109: 814–820
- European Respiratory Task Force. European Society Guidelines on the use of nebulizers. Eur RespirJ 2001; 18: 228–242
- Trofast J, Osterberg K, Kallstrom B L, Waldeck B. Steric aspects of agonism and antagonism at beta-adrenoceptors: synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers. Chirality 1991; 3: 443–450
- Handley D A, Senanayake C H, Dutczak W, Benovic J L, Walle T, Penn R B, Wilkinson H S, Tanoury G J, Andersson R G, Johansson F, Morley J. Biological actions of formoterol isomers. J. Pulm Pharmacol Ther 2002; 15: 135–145
- Zhang X Y, Zhu F X, Olszewski M A, Robinson N E. Effects of enantiomers of β2-agonists on ACh release and smooth muscle contraction in trachea. AmJ Physiol 1998; 274: L32–38
- Schmidt D, Kallstrom B L, Waldeck B, Branscheid D, Magnussen H, Rabe K F. The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. Naunyn Schmiedebergs Arch Pharmacol 2000; 361: 405–409
- World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects, http://www.wma.net/e/policy/b3.htm
- Crapo R O, Morris A H, Gardner R M. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123: 659–664
- Bestall J C, Paul E A, Garrod R, Jones P W, Wedzicha J A. Usefulness of the Medical Research Council (MRC) dyspnea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581–586
- Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982; 38: 29–41
- Donohue J F. Minimal clinically important differences in COPD lung function. COPD: J Chronic Obstructive Pul Dis 2005; 2: 111–124
- Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M, SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26
- Salpeter S R, Buckley N S, Ormiston T M, Salpeter E E. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904–912
- Calverley P MA, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New EngJ Med 2007; 356: 775–789
- Dolovich M B, Ahrens R C, Hess D R, Anderson P, Dhand R, Rau J L, Smaldone G C, Guyatt G. American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest 2005; 127: 335–371